| scholarly article | Q13442814 |
| P50 | author | Tadeusz Pieńkowski | Q38290512 |
| Daniil Stroyakovskiy | Q58237771 | ||
| Laura Biganzoli | Q60658485 | ||
| Xavier Pivot | Q66829173 | ||
| Ava Kwong | Q67423533 | ||
| P2093 | author name string | F A Franke | |
| B Xu | |||
| P Mainwaring | |||
| C Thomssen | |||
| D Pereira | |||
| K I Pritchard | |||
| B Kaufman | |||
| J-Y Pierga | |||
| A Fabi | |||
| I E Smith | |||
| H Cortés-Funes | |||
| ATHENA Study Group | |||
| K Petrakova | |||
| B De Valk | |||
| I Koza | |||
| J L González-Trujillo | |||
| P2860 | cites work | The biology of VEGF and its receptors | Q27860704 |
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer | Q33561160 | ||
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | Q34022546 | ||
| Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results | Q34524041 | ||
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 | ||
| The function of vascular endothelial growth factor | Q37470400 | ||
| Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis | Q37501707 | ||
| Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. | Q42669075 | ||
| Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study | Q43281857 | ||
| Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. | Q46029883 | ||
| Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment | Q46423648 | ||
| P433 | issue | 3 | |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| bevacizumab | Q413299 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 595-602 | |
| P577 | publication date | 2010-09-05 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients | |
| P478 | volume | 22 |
| Q38839151 | A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer |
| Q51319007 | A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. |
| Q99565938 | An isoflavone derivative potently inhibits the angiogenesis and progression of triple-negative breast cancer by targeting the MTA2/SerRS/VEGFA pathway |
| Q39034717 | Angiopoietin pathway gene expression associated with poor breast cancer survival |
| Q26822432 | Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials |
| Q26751226 | Antiangiogenic mechanisms and factors in breast cancer treatment |
| Q47111400 | Antiangiogenic therapy in breast cancer |
| Q53834125 | Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. |
| Q37963955 | Benefit-risk assessment of bevacizumab in the treatment of breast cancer. |
| Q36248498 | Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence |
| Q35696743 | Bevacizumab in the treatment of metastatic breast cancer: friend or foe? |
| Q37882684 | Bevacizumab-induced hypertension: pathogenesis and management |
| Q38260176 | Bevacizumab: a review of its use in advanced cancer |
| Q37950522 | Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer |
| Q31157714 | Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. |
| Q34609696 | Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer |
| Q64237467 | Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France |
| Q38056761 | Current and emerging new treatment strategies for mantle cell lymphoma |
| Q37181231 | Dyspnea Management in Early Stage Lung Cancer: A Palliative Perspective |
| Q35607779 | Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer |
| Q37961957 | Emerging drugs in metastatic breast cancer: an update |
| Q30657829 | First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. |
| Q38005357 | Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers |
| Q57074570 | Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study |
| Q37321051 | New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting |
| Q26865260 | Newer therapies for the treatment of metastatic breast cancer: a clinical update |
| Q38322346 | Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue? |
| Q27690879 | Optimal management of breast cancer in the elderly patient: current perspectives |
| Q54459895 | Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience. |
| Q33949406 | Risks and benefits with bevacizumab: evidence and clinical implications |
| Q49996824 | Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations |
| Q37903602 | Safety of bevacizumab in patients with metastatic breast cancer |
| Q38046514 | Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer |
| Q33628383 | Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer |
| Q45759415 | Taxane-Induced Peripheral Neurotoxicity. |
| Q36865945 | The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most? |
| Q39403423 | The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis |
| Q38160648 | The life, death, and attempted rebirth of bevacizumab in breast cancer |
| Q26785496 | Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer |
| Q37887823 | Trials of bevacizumab in breast cancer--a safety review |
| Q38046584 | Triple-negative breast cancer in the older population |
| Q35445151 | Use of bevacizumab as a first-line treatment for metastatic breast cancer |
| Q24202199 | Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer |
| Q30651989 | Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy. |
Search more.